Skip to main content
SpringerLink
Log in

Autism

Current Theories Regarding its Pathogenesis and Implications for Rational Pharmacotherapy

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Autism is a pervasive developmental disorder that is aetiologically and clinically heterogeneous. Twin and family-genetic studies provide evidence for strong genetic components. An international consortium using an affected sib pair strategy has found a promising linkage to a region on chromosome 7. In 10 to 15% of cases autism is due to associated medical conditions that affect normal brain functioning. Postmortem studies on small case series report cellular abnormalities in the limbic system and cerebellum. Between 10 and 20% of individuals with autism have macrocephalia, which is in accordance with magnetic resonance imaging (MRI) findings of an increased total brain tissue volume and enlargement most prominent in the occipital and parietal lobes. The most robust and well replicated neurobiological abnormality in autism is an elevation of whole blood serotonin (5-hydroxytryptamine; 5-HT) found in over 30% of patients. Pharmacological interventions with serotonin reuptake inhibitors or with atypical neuroleptics that block both dopamine (D2) and serotonin (5-HT2) receptors seem to offer clinical benefit and merit further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. American Psychiatric Association (APA), Diagnostic and statistical manual of mental disorders, 4th ed. (DSM-IV). Washington DC: APA, 1994

    Google Scholar 

  2. World Health Organization. ICD-10. Classification of mental and behavioural disorders. Clinical description and diagnostic guidelines. Geneva: WHO, 1992

    Google Scholar 

  3. Lord C, Rutter M. Autism and pervasive developmental disorders. In: Rutter M, Taylor E, Hersov L, editors. Child and adolescent psychiatry, modern approaches. Oxford: Blackwell Science, 1995: 569–93

    Google Scholar 

  4. Buitelaar JK, Van der Gaag RJ, Klin A, et al. Exploring the boundaries of PDD-NOS: analyses of data from the DSM-IV autistic disorder field trial. J Autism Dev Disord 1999; 29: 33–43

    PubMed  CAS  Google Scholar 

  5. Buitelaar JK, Van der Gaag RJ. Diagnostic rules for children with PDD-NOS and multiple complex developmental disorder. J Child Psychol Psychiatry 1998; 39: 911–20

    PubMed  CAS  Google Scholar 

  6. Smalley SL. Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder. Am J Hum Genet 1997; 60: 1276–82

    PubMed  CAS  Google Scholar 

  7. Folstein S, Rutter ML. Infantile autism: a genetic study of 21 twin pairs. J Child Psychol Psychiatry 1977; 18: 297–312

    PubMed  CAS  Google Scholar 

  8. Steffenburg S, Gillberg C, Helgren L, et al. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry 1989; 30: 405–16

    PubMed  CAS  Google Scholar 

  9. Bailey A, Le Couteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995; 25: 63–77

    PubMed  CAS  Google Scholar 

  10. Bolton P, Macdonald H, Pickles A, et al. A case-control family history study of autism. J Child Psychol Psychiatry 1994; 35: 877–900

    PubMed  CAS  Google Scholar 

  11. Pickles A, Bolton P, Macdonald H, et al. Latent-class analysis of recurrence risks for complex phenotypes with selection and measurement error: a twin and family history study of autism. Am J Hum Genet 1995; 57: 717–26

    PubMed  CAS  Google Scholar 

  12. International Molecular Genetic Study of Autism Consortium. A full genome screen for autism with evidence for linkage to a region on chromosome 7q. Hum Mol Genet 1998; 7: 571–8

    CAS  Google Scholar 

  13. Rutter M, Bailey A, Bolton P, et al. Autism and known medical conditions: myth and substance. J Child Psychol Psychiatry 1994; 35: 311–22

    PubMed  CAS  Google Scholar 

  14. Bolton PF, Griffiths PD. Association of tuberous sclerosis of temporal lobes with autism and atypical autism [see comments]. Lancet 1997; 349: 392–5

    PubMed  CAS  Google Scholar 

  15. Bolton PF, Murphy M, Macdonald H, et al. Obstetric complications in autism: consequences or causes of the condition? J Am Acad Child Adolesc Psychiatry 1997; 36: 272–81

    PubMed  CAS  Google Scholar 

  16. Bailey A, Phillips W, Rutter M. Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. J Child Psychol Psychiatry 1996; 37: 89–126

    PubMed  CAS  Google Scholar 

  17. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 637–41

    PubMed  CAS  Google Scholar 

  18. D’Eufeinia P. Abnormal intestinal permeability in children with autism. Acta Paediatrica 1996; 85: 1076–9

    Google Scholar 

  19. Chen RT, DeStephano F. Vaccine adverse events; causal or coincidental? Lancet 1998; 351: 611–2

    PubMed  CAS  Google Scholar 

  20. Horvath K, Stefanatos G, Sokolski K, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Physicians 1998; 9: 9–15

    CAS  Google Scholar 

  21. Happe F, Frith U. The neuropsychology of autism. Brain 1996; 119: 1377–400

    PubMed  Google Scholar 

  22. Bauman ML. Brief report: neuroanatomic observations of the brain in pervasive developmental disorders. J Autism Dev Disord 1996; 26: 199–203

    PubMed  CAS  Google Scholar 

  23. Kemper TL, Bauman ML. The contribution of neuropathologic studies to the understanding of autism. Neurol Clin 1993; 11: 175–87

    PubMed  CAS  Google Scholar 

  24. Bailey A, Luthert P, Dean A, et al. A clinicopathological study of autism. Brain 1998; 121: 889–905

    PubMed  Google Scholar 

  25. Woodhouse W, Bailey A, Rutter M, et al. Head circumference in autism and other pervasive developmental disorders. J Child Psychol Psychiatry 1996; 37: 665–71

    PubMed  CAS  Google Scholar 

  26. Lainhart JE, Piven J, Wzorek M, et al. Macrocephaly in children and adults with autism. J Am Acad Child Adolesc Psychiatry 1997; 36: 282–90

    PubMed  CAS  Google Scholar 

  27. Piven J, Berthier ML, Starkstein SE, et al. Magnetic resonance imaging evidence for a defect of cerebral cortical development in autism. Am J Psychiat 1990; 147: 734–9

    PubMed  CAS  Google Scholar 

  28. Piven J, Arndt S, Bailey J, et al. An MRI study of brain size in autism. Am J Psychiatry 1995; 152: 1145–9

    PubMed  CAS  Google Scholar 

  29. Piven J, Arndt S, Bailey J, et al. Regional brain enlargement in autism: a magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry 1996; 35: 530–6

    PubMed  CAS  Google Scholar 

  30. Filipek PA. Brief report: neuroimaging in autism: the state of the science 1995. J Autism Dev Disord 1996; 26: 211–5

    PubMed  CAS  Google Scholar 

  31. Courchesne E, Yeung-Courchesne R, Press GA, et al. Hypoplasia of cerebellar vermal lobules VI and VII in autism. N Engl J Med 1988; 318: 1349–54

    PubMed  CAS  Google Scholar 

  32. Courchesne E, Saitoh O, Townsend JP, et al. Cerebellar hypoplasia and hyperplasia in infantile autism. Lancet 1994; 343: 63–4

    PubMed  CAS  Google Scholar 

  33. Piven J, Saliba K, Bailey J, et al. An MRI study of autism: the cerebellum revisited. Neurology 1997; 49: 546–51

    PubMed  CAS  Google Scholar 

  34. Hashimoto T, Tayama M, Miyazaki M, et al. Reduced brainstem size in children with autism. Brain Dev 1992; 14: 94–7

    PubMed  CAS  Google Scholar 

  35. Hashimoto T, Tayama M, Miyazaki M, et al. Brainstem and cerebellar vermis involvement in autistic children. J Child Neurol 1993; 8: 149–52

    PubMed  CAS  Google Scholar 

  36. Hashimoto T, Tayama M, Murakawa K, et al. Development of the brainstem and cerebellum in autistic patients. J Autism Dev Disord 1995; 25: 1–18

    PubMed  CAS  Google Scholar 

  37. Piven J, Nehme E, Barta P, et al. Magnetic resonance imaging in autism: measurement of the cerebellum, pons, and fourth ventricle. Biol Psychiatry 1992; 31: 491–504

    PubMed  CAS  Google Scholar 

  38. Hsu M, Yeung-Courchesne R, Courchesne E, et al. Absence of magnetic resonance imaging evidence of pontine abnormality in infantile autism. Arch Neurol 1991; 48: 1160–3

    PubMed  CAS  Google Scholar 

  39. Piven J, Bailey J, Ranson BJ, et al. An MRI study of the corpus callosum in autism. Am J Psychiatry 1997; 154: 1051–6

    PubMed  CAS  Google Scholar 

  40. Zilbovicius M, Garreau B, Samson Y, et al. Delayed maturation of the frontal cortex in childhood autism. Am J Psychiatry 1995; 152: 248–52

    PubMed  CAS  Google Scholar 

  41. Minshew NJ, Goldstein G, Dombrowski SM, et al. A preliminary 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes. Biol Psychiatry 1993; 33: 762–73

    PubMed  CAS  Google Scholar 

  42. Cohen DJ, Caparulo BK, Shaywitz BA, et al. Dopamine and serotonin metabolism in neuropsychiatrically disturbed children: CSF homovanillic acid and 5-hydroxy-indoleacetic acid. Arch Gen Psychiatry 1977; 34: 545–50

    PubMed  CAS  Google Scholar 

  43. Gillberg C, Svennerholm L, Hamilton-Hellberg C. Childhood psychosis and monoamine metabolites in spinal fluid. J Autism Dev Dis 1983; 13: 383–96

    CAS  Google Scholar 

  44. Ross DL, Klykylo WM, Anderson GM. Cerebrospinal fluid indolamines and monoamine effects in fenfluramine treatment of autism. Ann Neurol 1985; 18: 394–6

    Google Scholar 

  45. Gillberg C, Svennerholm L. CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry 1987; 151: 89–94

    PubMed  CAS  Google Scholar 

  46. Narayan M, Srinath S, Anderson GM, et al. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry 1993; 33: 630–5

    PubMed  CAS  Google Scholar 

  47. Launay JM, Bursztejn C, Ferrari P, et al. Catecholamine metabolism in infantile autism: a controlled study of 22 autistic children. J Autism Dev Dis 1987; 17: 553–6

    Google Scholar 

  48. Garreau B, Barthélémy C, Jouve J, et al. Urinary homovanillic acid levels of autistic children. Dev Med Child Neurol 1988; 30: 93–8

    PubMed  CAS  Google Scholar 

  49. Minderaa RB, Anderson GM, Volkmar FR, et al. Neurochemical study of dopamine functioning in autistic and normal subjects. J Am Acad Child Adolesc Psychiatry 1989; 28: 190–4

    PubMed  CAS  Google Scholar 

  50. Martineau J, Herault J, Petit E, et al. Catecholaminergic metabolism and autism. J Autism Dev Disord 1994; 36: 688–97

    CAS  Google Scholar 

  51. Hameury L, Roux S, Barthelemy C, et al. Quantified multidimensional assessment of autism and other pervasive developmental disorders. Application for bioclinical research. Eur Child Adolesc Psychiatry 1995; 4: 123–35

    PubMed  CAS  Google Scholar 

  52. Ernst M, Zametkin AJ, Matochik JA, et al. Low medial prefrontal dopaminergic activity in autistic children [letter]. Lancet 1997; 350: 638

    PubMed  CAS  Google Scholar 

  53. Minderaa RB, Anderson GM, Volkmar FR, et al. Whole blood serotonin and tryptophan in autism: temporal stability and the effects of medication. J Autism Dev Disord 1989; 19: 129–36

    PubMed  CAS  Google Scholar 

  54. Anderson GM, Home WC, Chatterjee D, et al. The hyperserotonemia of autism. Ann NY Acad Sci 1990; 600: 331–42

    PubMed  CAS  Google Scholar 

  55. Cook EHJ, Leventhal BL, Heller W, et al. Autistic children and their first-degree relatives: relationships between serotonin and norepinephrine levels and intelligence. J Neuropsychiatry Clin Neurosci 1990; 2: 268–74

    PubMed  Google Scholar 

  56. Partington MW, Tu JB, Wong CY Blood serotonin levels in severe mental retardation. Dev Med Child Neurol 1973; 15: 616–27

    PubMed  CAS  Google Scholar 

  57. McBride PA, Anderson GM, Hertzig ME, et al. Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1998; 37: 767–76

    PubMed  CAS  Google Scholar 

  58. Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr 1996; 8: 348–54

    PubMed  CAS  Google Scholar 

  59. Cook Jr EH, Courchesne R, Lord C, et al. Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 1997; 2: 247–50

    PubMed  Google Scholar 

  60. Klauck SM, Poustka F, Benner A, et al. Serotonin transporter (5-HTT) gene variants associated with autism? Hum Mol Genet 1997; 6: 2233–8

    PubMed  CAS  Google Scholar 

  61. Herault J, Petit E, Martineau J, et al. Serotonin and autism: biochemical and molecular biology features. Psychiatry Res 1996; 65: 33–43

    PubMed  CAS  Google Scholar 

  62. Cuccaro ML, Wright HH, Abramson RK, et al. Whole blood serotonin and cognitive functioning in autistic individuals and their first-degree relatives. J Neuropsychiatry Clin Neurosci 1993; 2: 268–74

    Google Scholar 

  63. Hoshino Y, Tachibana R, Watanabe M, et al. Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction. Jpn J Psychiatry Neurol 1984; 26: 937–45

    Google Scholar 

  64. McBride PA, Anderson GM, Hertzig ME, et al. Serotonergic responsivity in male young adults with autistic disorder. Arch Gen Psychiatry 1989; 46: 213–21

    PubMed  CAS  Google Scholar 

  65. Chugani DC, Muzik O, Rothermel R, et al. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol 1997; 42: 666–9

    PubMed  CAS  Google Scholar 

  66. McDougle CJ, Naylor ST, Cohen DJ, et al. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 993–1000

    PubMed  CAS  Google Scholar 

  67. Panksepp J. A neurochemical theory of autism. Trends Neurosci 1979; 2: 174–7

    Google Scholar 

  68. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, et al. Plasma beta-endorphin concentrations in people with learning disability and self-injurious and/or autistic behaviour. Br J Psychiatry 1996; 168: 105–9

    PubMed  CAS  Google Scholar 

  69. Tordjman S, Anderson GM, McBride PA, et al. Plasma beta-endorphin, adrenocorticotropic hormone, and Cortisol in autism. J Child Psychol Psychiatry 1997; 38: 705–15

    PubMed  CAS  Google Scholar 

  70. Insel TR. A neurobiological basis of social attachment. Am J Psychiatry 1997; 154: 726–35

    PubMed  CAS  Google Scholar 

  71. Freeman WJ. Neurohumoral brain dynamics of social group formation. Implications for autism. Ann N Y Acad Sci 1997; 807: 501–3

    PubMed  CAS  Google Scholar 

  72. Modahl C, Green L, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998; 43: 270–7

    PubMed  CAS  Google Scholar 

  73. Buitelaar JK. Attachment and social withdrawal in autism: hypotheses and findings. Behaviour 1995; 132: 319–50

    Google Scholar 

  74. Howlin P, Rutter M. Treatment of autistic children. New York: Wiley & Sons, 1987

    Google Scholar 

  75. Howlin P. Practitioner review: psychological and educational treatments for autism. J Child Psychol Psychiatry 1998; 39: 307–22

    PubMed  CAS  Google Scholar 

  76. Geller E, Ritvo ER, Freeman BJ. Preliminary observations on the effects of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 1982; 307: 165–9

    PubMed  CAS  Google Scholar 

  77. Ritvo ER, Freeman BJ, Geller E, et al. Effects of fenfluramine on 14 outpatients with the syndrome of autism. J Am Acad Child Psychiatry 1983; 22: 549–58

    PubMed  CAS  Google Scholar 

  78. Schuster CR, Lewis M, Seiden LS. Fenfluramine: neurotoxicity. Psychopharmacol Bull 1986; 22: 148–51

    PubMed  CAS  Google Scholar 

  79. Realmuto GM, Jensen J, Klykylo W, et al. Untoward effects of fenfluramine in autistic children. J Clin Psychopharmacol 1986; 6: 350–5

    PubMed  CAS  Google Scholar 

  80. Buitelaar JK. Psychopharmacological approaches to childhood psychotic disorders. In: Den Boer JA, Westenberg HGM, Van Praag HM, editors. Advances in the neurobiology of schizophrenia. London: Wiley & Sons, 1995: 429–57

    Google Scholar 

  81. McDougle CJ, Price LH, Volkmar FR, et al. Clomipramine in autism: preliminary evidence of efficacy (case study). J Am Acad Child Adolesc Psychiatry 1992; 31: 746–50

    PubMed  CAS  Google Scholar 

  82. Brodkin ES, McDougle CJ, Naylor ST, et al. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 1997; 7: 109–21

    PubMed  CAS  Google Scholar 

  83. Gordon CT, State RC, Nelson JE, et al. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50: 441–7

    PubMed  CAS  Google Scholar 

  84. Sanchez LE, Campbell M, Small AM, et al. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996; 35: 537–44

    PubMed  CAS  Google Scholar 

  85. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 1001–8

    PubMed  CAS  Google Scholar 

  86. McDougle CJ. Psychopharmacology of autism (paper presented at XIth Congress of the ECNP). Eur Neuropsychopharmacol 1998; Suppl. 2: S107

    Google Scholar 

  87. Riddle M. Fluvoxamine in children and adolescents with OCD. Proceedings X World Congress of Psychiatry, Madrid 1996; 2: 141

    Google Scholar 

  88. Cook EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31: 739–45

    PubMed  Google Scholar 

  89. Hellings JA, Kelley LA, Gabrielli WF, et al. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996; 57: 333–6

    PubMed  CAS  Google Scholar 

  90. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989; 9: 122–5

    PubMed  CAS  Google Scholar 

  91. Ratey JJ, Sovner R, Mikkelsen E, et al. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry 1989; 50: 382–4

    PubMed  CAS  Google Scholar 

  92. Ratey J, Sovner R, Parks A, et al. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. J Clin Psychiatry 1991; 52: 159–62

    PubMed  CAS  Google Scholar 

  93. Buitelaar JK, Van der Gaag RJ, Van der Hoeven J. Effects of buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: open pilot data. J Clin Psychiatry 1998; 59: 56–9

    PubMed  CAS  Google Scholar 

  94. Anderson LT, Campbell M, Graga DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984; 141: 1195–202

    PubMed  CAS  Google Scholar 

  95. Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989; 19: 227–39

    PubMed  CAS  Google Scholar 

  96. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous administration. J Am Acad Child Adolesc Psychiatry 1989; 28: 87–92

    PubMed  CAS  Google Scholar 

  97. Campbell M, Adams P, Perry R, et al. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 1988; 24: 251–5

    PubMed  CAS  Google Scholar 

  98. Naruse H, Nagahata M, Nakane Y, et al. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using cross-over design. Acta Paedopsychiatrica 1982; 48: 173–84

    PubMed  CAS  Google Scholar 

  99. Ernst M, Magee HJ, Gonzalez NM, et al. Pimozide in autistic children. Psychopharmacol Bull 1992; 28: 187–91

    PubMed  CAS  Google Scholar 

  100. Hardan A, Johnson K, Johnson C, et al. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996; 35: 1551–6

    PubMed  CAS  Google Scholar 

  101. Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998; 37: 372–6

    PubMed  CAS  Google Scholar 

  102. Perry R, Pataki C, Munoz Silva DM, et al. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 1997; 7: 167–79

    PubMed  CAS  Google Scholar 

  103. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36: 685–93

    PubMed  CAS  Google Scholar 

  104. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6: 177–90

    PubMed  CAS  Google Scholar 

  105. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33: 155–9

    PubMed  CAS  Google Scholar 

  106. Geller WK, Zuiderwijk PB. Risperidone-induced hepatotoxicity? [letter]. J Am Acad Child Adolesc Psychiatry 1998; 37: 246–7

    PubMed  CAS  Google Scholar 

  107. Kumra S, Herion D, Jacobsen LK, et al. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997; 36: 701–5

    PubMed  CAS  Google Scholar 

  108. McDougle CJ, Holmes JP, Carlson DC, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55: 633–41

    PubMed  CAS  Google Scholar 

  109. Campbell M, Fish B, David R, et al. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Childhood Schizophr 1972; 2: 343–57

    CAS  Google Scholar 

  110. Bloom ASR. Methylphenidate-induced delusional disorder in a child with attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1988; 27(1): 88–9

    PubMed  CAS  Google Scholar 

  111. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25: 283–94

    PubMed  CAS  Google Scholar 

  112. Aman MG, Marks RE, Turbott SH, et al. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 1991; 30: 246–56

    PubMed  CAS  Google Scholar 

  113. Leboyer M, Bouvard MP, Launay J, et al: brief report: a double-blind study of naltrexone in infantile autism. J Autism Dev Disord 1992; 22: 309–19

    PubMed  CAS  Google Scholar 

  114. Campbell M, Anderson LT, Small AM, et al. Naltrexone in autistic children — behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993; 32: 1283–91

    PubMed  CAS  Google Scholar 

  115. Kolmen BK, Feldman HM, Handen BL, et al. Naltrexone in young autistic children — A double-blind, placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995; 34: 223–31

    PubMed  CAS  Google Scholar 

  116. Kolmen BK, Feldman HM, Handen BL, et al. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997; 36: 1570–8

    PubMed  CAS  Google Scholar 

  117. Willemsen-Swinkels SHN, Buitelaar JK, Van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39: 1023–31

    PubMed  CAS  Google Scholar 

  118. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, et al. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 1995; 58: 203–15

    PubMed  CAS  Google Scholar 

  119. Willemsen-Swinkels SHN, Buitelaar JK, Van Berckelaer-Onnes IA, et al. Brief report: six-months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design. J Autism Dev Disord 1999; 29: 167–9

    PubMed  CAS  Google Scholar 

  120. Willemsen-Swinkels SHN, Buitelaar JK, Nijhof G, et al. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry 1995; 52: 766–73

    PubMed  CAS  Google Scholar 

  121. Fankhauser MP, Karumanchi VC, German ML, et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53: 77–82

    PubMed  CAS  Google Scholar 

  122. Ratey JJ, Lindem KJ. Beta-blockers as primary treatment for aggression and self-injury in the developmentally disabled. In: Ratey JJ, editor. Mental retardation. Developing pharmacotherapies. Washington DC: American Psychiatric Press, 1991: 51–82

    Google Scholar 

  123. Ratey JJ, Bemporad J, Sorgi P, et al. Brief report: open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord 1987; 17: 439–46

    PubMed  CAS  Google Scholar 

  124. Komoto JM, Usui S, Hirata J. Infantile autism and affective disorder. J Autism Dev Disord 1984; 14: 81–4

    PubMed  CAS  Google Scholar 

  125. Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol 1987; 7: 401–5

    PubMed  CAS  Google Scholar 

  126. Buitelaar JK. Self-injurious behavior in retarded children, clinical phenomena and biological mechanisms. Acta Paedopsychiatrica 1993; 56: 105–11

    PubMed  CAS  Google Scholar 

  127. Gillberg C. The treatment of epilepsy in autism. J Autism Dev Disord 1991; 21: 61–77

    PubMed  CAS  Google Scholar 

  128. Plioplys A. Autism: electroencephalographic abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med 1994; 148: 220–2

    PubMed  CAS  Google Scholar 

  129. Howlin P. Behavioural techniques to reduce self-injurious behaviour in children with autism. Acta Paedopsychiatrica 1993; 56: 75–84

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Child Psychiatry, University Medical Centre Utrecht, Utrecht, The Netherlands

    Jan K. Buitelaar & Sophie H. N. Willemsen-Swinkels

Authors
  1. Jan K. Buitelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie H. N. Willemsen-Swinkels
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan K. Buitelaar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buitelaar, J.K., Willemsen-Swinkels, S.H.N. Autism. Pediatr-Drugs 2, 67–81 (2000). https://doi.org/10.2165/00148581-200002010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200002010-00006

Keywords

Search

Navigation